1984 - ESTABLISHMENT
Realizing the need for qualified raw materials in the Brazilian pharmaceutical market, Giuseppe Frangioni establishes Blanver. It quickly becomes one of the main market suppliers, due to a high investment in technology and technical support.
1988 - INTERNATIONALIZATION
Already well established in the Brazilian market, Blanver starts the internationalization process, with a strategy of exclusive distributors for each territory.
1995 - FOOD SEGMENT
Another important milestone was when we started exploring the food sector. With some adaptations, microcrystalline cellulose supplied for pharmaceutical products could be used in several food products such as ice cream, dairy beverages, heavy cream, among others.
1996 - PHARMACEUTICAL UNIT
With globalization and the growing international competition, Blanver was already supplying the Brazilian market with a synergic and innovative product line complementing its portfolio, and this year it establishes its pharmaceutical unit, offering medication manufacturing outsourcing services, with intensive and high quality technical support.
1998 - OFFICE IN EUROPE
With the goal to explore opportunities in Europe and later in Asia, Africa and Oceania, we opened an office in Spain.
2000 - BLANVER USA
At the turn of the century Blanver started operating in the United States, the largest pharmaceutical market. With the opening of the office and four strategically located distribution centers, we started to directly offer our products to customers, supplying high quality products, prompt delivery and with local technical support.
2005 - ANTIRETROVIRAL FINISHED DOSAGE FORMULATIONS
Our start on the antiretroviral segment happened by providing outsourcing production service of HIV medications for official Brazilian labs. This year we also had the patent registration of the medicine Didanosine Enteric, developed together with research institutes.
2009 - NEW PHARMACEUTICAL UNIT
We opened a new pharmaceutical unit, with a modern structure and a larger production capacity. From a high technology and R&D investment, we began to develop our own finished dosage formulations.
2011 - 1st OWN MEDICATION
Launch of Blanver’s first medication – Tenofovir, for HIV and Hepatitis B treatment.
2012 - NEW PATENTED MANUFACTURING PROCESS
Implementation of new patented raw materials manufacturing process, resulting in increased productivity and a significant decrease in electricity, water, ethanol and natural gas consumption, with important environment benefits.
2013 - 2nd OWN MEDICATION
Launch of Blanver’s second medication – Duplivir (Tenofovir + Lamivudine), considered an innovation in HIV treatment, as it combines two APIs in one tablet.
2014 - ELECTRICITY COGENERATION PROJECT
By implementing the electricity cogeneration system we started to produce 80% of all electricity needed by our raw materials plant, resulting in one of the most important actions regarding sustainability.
2015 - STRATEGIC CHANGE
New direction for the Pharmaceutical Unit: Discontinuation of the outsourcing division and focus on development and production of our own finished dosage formulations and on the internationalization plan. Entry in Active Pharmaceutical Ingredients (APIs) segment via acquisition of CYG Biotech company
2017 - STRATEGIC CHANGE
Sale of the excipients and ingredients division.
2018 - 3rd MEDICINE
Granted registration of our tenofovir + emtricitabine medicine, the first generic for prevention of the HIV virus manufactured in Brazil.
2023 - VISION FOR THE FUTURE
To be among the 500 largest Brazilian companies by 2023.
To develop innovative medicines necessary for society.
To find new strategic partners and new markets.